In today's ACT Brief, we explore practical community engagement strategies that drive representative enrollment, how sponsors ...
In today's ACT Brief, we explore practical steps sponsors can take to prepare for the plausible mechanism framework, how ...
In this Q&A, Mwango Kashoki, MD, MPH, SVP and global head of regulatory strategy at Parexel, breaks down the FDA's plausible ...
In this video interview, Del Smith, PhD, CEO and co-founder of Acclinate, outlines what a practical, sustained community ...
In today's ACT Brief, we explore how disease heterogeneity confounds natural history controls, the execution translation gap ...
In this video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, ...
In today's ACT Brief, we examine how protocol interpretation and source document preparation delay study startup, how the ...
In a recent video interview with Applied Clinical Trials, Mwango Kashoki, MD, MPH, senior vice president and global head of ...
In today's ACT Brief, we examine Thermo Fisher's expanded real-world data access through HealthVerity, how FHIR-based ...
Two classic translational blocks are compounded by an execution gap characterized by weak cross-functional mobilization, slow ...
1. FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results. News release. FDA. April 13, 2026.
In today's ACT Brief, we explore biological and dosing considerations for basket trial designs, how human-relevant data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results